APPENDIX C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Multiple Technology Appraisal (MTA)

Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85)

Matrix of consultees and commentators

Consultees	**Commentators (no right to submit or appeal)**
Manufacturers/sponsors • Astellas Pharma (immediate-release tacrolimus, prolonged-release tacrolimus) • Bristol-Myers Squibb (belatacept) • Novartis Pharmaceuticals (basiliximab, everolimus, and mycophenolate sodium) • Roche Products (mycophenolate mofetil) • Sandoz (mycophenolate mofetil, immediate-release tacrolimus) • Sanofi (rabbit anti-human thymocyte immunoglobulin) • Teva (mycophenolate mofetil, immediate-release tacrolimus) Patient/carer groups • Kidney Research UK Professional groups • British Association of Urological Surgeons • British Renal Society • British Transplantation Society • ESPRIT • Renal Association • Royal College of Physicians Others • Department of Health • NHS England • Welsh Government	General • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland Comparator manufacturers • Novartis Pharmaceuticals (ciclosporin) • Sandoz (azathioprine) • Teva (azathioprine, ciclosporin, prednisolone) Relevant research groups • Cochrane Renal Group Assessment Group • National Institute for Health Research Health Technology Assessment Programme • Peninsula Technology Assessment Group (PenTAG) Associated Guideline Groups • None Public Health Groups • None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees
Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government; relevant NHS organisations in England and local health boards in Wales.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and consultee organisations representing patient/carers and professionals can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators
Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, the *British National Formulary*, and the British Medical Association.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).